Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

748 questions · 782 findings · 58 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 164 · 21%GRADE not reported 26 · 3.3%Very low 151 · 19.3%Low 222 · 28.4%Moderate 158 · 20.2%High 61 · 7.8%

Intervention not reported

Failure of first‐line therapy · women withe low‐risk GTN

The intervention probably leads to higher failure of first‐line therapy (moderate certainty).

1 finding from 1 review

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).

1 finding from 1 review

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).

1 finding from 1 review

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review